BPC-157 (Oral) vs Thymosin Beta-4
A side-by-side research comparison of BPC-157 (Oral) and Thymosin Beta-4 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | Thymosin Beta-4 |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Thymosin Beta-4 (Full Length) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | Sequesters G-actin to regulate cytoskeleton dynamics, promotes stem cell differentiation, and activates anti-inflammatory and anti-apoptotic pathways. |
| Molecular weight | 1419.53 Da | 4921 Da |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | ~6-8 hours |
| Bioavailability | ~40-60% oral (arginate salt form) | ~95% subcutaneous |
| Typical dose | 500 mcg - 1 mg | 1-5 mg |
| Frequency | 1-2x daily | 2-3x per week |
| Route | Oral capsule (arginate salt) | Subcutaneous injection |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
Thymosin Beta-4 reported benefits
- Comprehensive tissue repair
- Cardiac regeneration
- Neurological recovery
- Corneal healing
- Anti-fibrotic effects
Related comparisons
Research and educational reference only. Not medical advice.